Heart Failure with Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic Enigma


DOI: 10.1007/s12170-011-0184-2

Cite this article as:
Bhuiyan, T. & Maurer, M.S. Curr Cardiovasc Risk Rep (2011) 5: 440. doi:10.1007/s12170-011-0184-2


Heart failure with preserved ejection fraction (HFPEF) is increasing in prevalence with the aging of the population, and morbidity and mortality rates are comparable to that of heart failure with reduced ejection fraction (HFREF). The diagnosis can be difficult to make, especially in older adults, stemming from the presence of multiple co-morbid illnesses with confounding symptoms. New diagnostic tools have resulted in guidelines proposed to define and diagnose HFPEF. Recent literature focusing on the pathophysiology underlying this disease suggests multiple mechanisms are involved in the generation of the phenotype, such as abnormal relaxation and ventricular-vascular coupling, chronotropic incompetence, volume overload, and redistribution and /or endothelial dysfunction. Currently, no clinically proven treatments are shown to decrease morbidity and mortality in this population; however, there may be a novel multidisciplinary and multistage treatment strategy that can be studied to address this complex disease which incorporates pharmacologic and non-pharmacologic therapeutics.


Heart failure Diastolic heart failure Heart failure preserved ejection fraction Heart failure normal ejection fraction Heart failure diagnosis Heart failure treatment 

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of CardiologyColumbia University Medical CenterNew YorkUSA
  2. 2.Clinical Cardiovascular Research Laboratory for the ElderlyAllen Hospital of New York Presbyterian HospitalNew YorkUSA

Personalised recommendations